# Antimicrobial Stewardship in Canine Pyoderma: From Empiric to Culture-Guided Therapy


## Key Takeaways

- Canine pyoderma is primarily caused by *Staphylococcus pseudintermedius*, a commensal organism that causes disease when host defenses are compromised, often secondary to underlying conditions like allergic dermatitis or endocrinopathy.
- Topical antimicrobial therapy (e.g., chlorhexidine, benzoyl peroxide, ethyl lactate) is the recommended first-line treatment for surface and superficial pyodermas, with systemic antimicrobials reserved for deep infections or superficial cases unresponsive to topical treatment.
- Cytology is mandatory prior to any antimicrobial prescription to confirm bacterial infection and guide therapy; culture and susceptibility testing are indicated for recurrent pyoderma, deep pyoderma, suspected methicillin resistance, or failure of first-line systemic therapy.
- Methicillin-resistant *Staphylococcus pseudintermedius* (MRSP) is a significant concern, with pooled prevalence rates approaching 30% in some regions, necessitating culture-guided therapy due to broader resistance profiles to commonly used agents.
- Initial systemic antimicrobial courses are recommended for 2 weeks for superficial and 3 weeks for deep pyoderma, followed by mandatory re-evaluation with cytology to determine the need for continued treatment, avoiding prolonged therapy without evidence of active infection.
- Addressing the underlying primary dermatosis is critical for preventing recurrence; failure to identify and manage triggers like allergies or endocrine disorders constitutes a stewardship failure, regardless of antimicrobial selection.

---

Canine pyoderma is among the most frequent indications for systemic antimicrobial prescribing in small animal practice, and the emergence of multidrug-resistant staphylococci has made routine antibiotic use increasingly difficult to justify. This article provides a practical framework for veterinarians managing bacterial skin disease in dogs, moving from a default of systemic therapy toward topical-first management and culture-guided selection when systemic drugs are unavoidable. The guidance applies to first-opinion and referral settings and addresses the clinical reasoning, diagnostic steps, and monitoring protocols that support responsible antimicrobial use.

The approach rests on a central principle: most canine pyodermas are secondary to an underlying skin disease, and the infection itself is often manageable with topical therapy alone. Systemic antimicrobials should be reserved for deep pyoderma and for superficial disease that fails topical treatment, as emphasized in the [ISCAID antimicrobial use guidelines for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/40338805/). This article explains how to classify pyoderma by depth, when to pursue bacterial culture, how to interpret susceptibility results in the context of staphylococcal resistance, and how to structure re-evaluation so that antimicrobial courses are neither under-treated nor prolonged without evidence.

## At a Glance

| Parameter | Clinical Decision Point |
|---|---|
| Pyoderma classification | Surface, superficial, or deep based on lesion morphology and histologic depth of involvement |
| First-line therapy | Topical antimicrobials (chlorhexidine, benzoyl peroxide, ethyl lactate) for surface and superficial disease |
| Systemic antimicrobial indication | Deep pyoderma, or superficial pyoderma unresponsive to adequate topical therapy |
| Pre-treatment cytology | Mandatory in all cases before any antimicrobial is prescribed |
| Initial systemic course | 2 weeks for superficial, 3 weeks for deep pyoderma, followed by mandatory re-examination |
| Culture indication | Recurrent pyoderma, deep pyoderma, suspected methicillin resistance, or failure of first-line systemic therapy |
| Resistance concern | Methicillin-resistant Staphylococcus pseudintermedius (MRSP) is prevalent and often multidrug-resistant |
| Re-evaluation standard | Clinical lesion scoring plus cytology at each re-check, continue treatment only while infection persists |

## Pathophysiology of Canine Pyoderma

Staphylococcus pseudintermedius is the primary bacterial agent in canine pyoderma, as confirmed by a [systematic review and meta-analysis of pyodermic dogs in Asia](https://pubmed.ncbi.nlm.nih.gov/42065810/). The organizm is a commensal of canine skin and mucosa, and disease develops when host defenses are compromised. Follicular colonization progresses to folliculitis when the skin barrier fails, often because of allergic dermatitis, endocrinopathy, ectoparasitism, or conformational factors such as skin folds. The depth of infection determines both clinical appearance and treatment strategy.

Surface pyoderma involves the stratum corneum without follicular invasion and includes conditions such as pyotraumatic dermatitis and intertrigo. Superficial pyoderma extends into the epidermis and hair follicle epithelium, producing papules, pustules, and epidermal collarettes. Deep pyoderma breaches the follicle wall and extends into the dermis or subcutis, causing furuncles, ulcers, and draining tracts. The distinction matters because topical therapy penetrates surface and superficial infections reliably, whereas deep infections require systemic drug delivery to reach bacteria beyond the follicular epithelium.

## The Resistance Problem

Methicillin-resistant S. pseudintermedius has become a global concern. The same [systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42065810/) reported a pooled MRSP prevalence of 30.7% among canine pyoderma isolates from Asian studies published between 2015 and 2024, with high heterogeneity across the included studies. MRSP isolates showed broader resistance profiles, particularly to oxacillin, clindamycin, and other commonly used agents. The zoonotic potential of methicillin-resistant staphylococci adds a public health dimension to routine pyoderma management, as noted in a [narrative review of changes in canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/29704943/).

Resistance emerges under selective pressure from antimicrobial use. Each systemic course eliminates susceptible organizms and permits resistant subpopulations to expand. This mechanism explains why repeated or prolonged antibiotic therapy is a risk factor for multidrug-resistant infection, and why stewardship efforts focus on reducing systemic exposure wherever topical alternatives are effective. The [ISCAID guidelines](https://pubmed.ncbi.nlm.nih.gov/40338805/) explicitly recommend topical therapy as the treatment of choice for surface and superficial pyoderma, reserving systemic drugs for cases where topical treatment is not effective or the infection is deep.

## Classification and Diagnostic Logic

Accurate classification precedes treatment decisions. Cytology should be performed in all cases before antimicrobials are used, per the [ISCAID guidelines](https://pubmed.ncbi.nlm.nih.gov/40556037/). Impression smears from intact pustules or under the edge of a crust reveal neutrophils and intracellular cocci in bacterial pyoderma. The absence of bacteria on cytology should prompt reconsideration of the diagnosis, including sterile pustular dermatoses, demodicosis, or dermatophytosis.

Lesion distribution and morphology guide depth classification. Intact pustules and papules indicate superficial infection. Epidermal collarettes, which form as pustules rupture and the roof peels back, are also superficial. Deep pyoderma presents with nodules, furuncles, hemorrhagic bullae, or draining tracts, often with pain on palpation. Interdigital furunculosis is a common deep presentation. When clinical signs are ambiguous, histopathology can confirm depth and exclude non-infectious mimics.

## Topical Therapy as First-Line Management

Topical antimicrobials with a low resistance profile, including chlorhexidine, benzoyl peroxide, and ethyl lactate, have been used for decades in veterinary dermatology, and newer alternatives continue to be explored, as summarized in a [review of topical therapy for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/36921021/). Chlorhexidine is the most extensively studied agent and is available in shampoos, wipes, foams, and sprays. Benzoyl peroxide adds follicular flushing and keratolytic activity, which is useful in deep or comedonal disease. Ethyl lactate is hydrolyzed to lactic acid and ethanol on the skin, creating an antibacterial environment.

Topical therapy requires adequate contact time. Shampoos should be left on for 10 minutes before rinsing, and treatment frequency typically starts at two to three times weekly, adjusted based on response. The choice of formulation matters: wipes and sprays suit localized lesions, while shampoos cover generalized disease. Owner compliance is a common failure point, and clear written instructions improve outcomes. The [review of topical options](https://pubmed.ncbi.nlm.nih.gov/36921021/) emphasizes that reducing systemic antibiotic use through effective topical therapy decreases microbial pressure and selection for multidrug-resistant bacteria.

## When Systemic Therapy Becomes Necessary

Systemic antimicrobials are indicated for deep pyoderma and for superficial pyoderma that does not respond to adequate topical therapy. The [ISCAID guidelines](https://pubmed.ncbi.nlm.nih.gov/40338805/) recommend an initial systemic course of 2 weeks for superficial and 3 weeks for deep pyoderma, with adjunctive topical treatment throughout. Re-examination at these time points is mandatory, not optional. The infection should be reassessed clinically and cytologically, and treatment continued only while active infection persists. Deep pyoderma often requires 6 to 12 weeks of therapy, but each extension should be justified by objective findings instead of habit.

Before starting systemic therapy, the clinician should identify and address the underlying primary disease. Pyoderma recurs when the trigger persists, and repeated antimicrobial courses without controlling the primary dermatosis constitute a stewardship failure regardless of drug selection. Referral for allergy work-up, endocrine testing, or dermatologic evaluation should be considered when the primary cause is not apparent or has not responded to first-line management.

## Diagnostic Workup: Cytology, Culture, and Susceptibility Testing

Cytology is the first and most consequential diagnostic step in every pyoderma case. The [ISCAID antimicrobial use guidelines](https://pubmed.ncbi.nlm.nih.gov/40338805/) require cytology before any antimicrobial is prescribed, whether topical or systemic. A stained impression smear, tape strip, or swab preparation should be evaluated for the presence of cocci, neutrophils with intracellular bacteria, and yeast. The distinction between surface, superficial, and deep pyoderma rests on cytologic findings combined with lesion morphology, and this classification determines whether topical therapy alone is appropriate or whether systemic drugs are required.

Culture and susceptibility testing is not indicated for every first presentation. The decision to culture should follow defined triggers. Culture is warranted when a superficial pyoderma fails to respond to two weeks of appropriate topical therapy, when deep pyoderma is diagnosed at presentation, when cytology reveals rod-shaped bacteria, or when the patient has received systemic antimicrobials within the preceding 30 days. Recurrent pyoderma, defined as more than three episodes in 12 months, also justifies culture before further systemic exposure. The [narrative review on changes in canine pyoderma management](https://pubmed.ncbi.nlm.nih.gov/29704943/) emphasizes that early microbiologic diagnosis supports identification of multidrug-resistant pathogens before treatment failure becomes entrenched.

Sample collection technique determines culture utility. For intact pustules, the surface should be cleaned with alcohol and allowed to dry before the pustule is ruptured with a sterile needle. The exudate is collected on a sterile swab and placed in transport medium. For deep pyoderma, biopsy for culture is preferred over surface swabs because surface contamination with commensal flora can obscure the true pathogen. When biopsy is performed, one sample is placed in sterile saline for culture and a second in formalin for histopathology. Abscesses and furuncles should be sampled by aspiration or by swabbing the deep portion of an opened lesion.

Interpretation of susceptibility results requires attention to the organizm identified. *Staphylococcus pseudintermedius* remains the primary pathogen in canine pyoderma, but the [systematic review and meta-analysis of Asian studies](https://pubmed.ncbi.nlm.nih.gov/42065810/) reports a pooled methicillin-resistant prevalence of 30.7%, with high heterogeneity across studies. A methicillin-resistant isolate should be assumed resistant to all beta-lactams regardless of in vitro results. Susceptibility testing for clindamycin should include evaluation for inducible resistance, as isolates that appear susceptible may still fail therapy. When culture yields a mixed population, the clinician must determine which organizm is driving the infection based on cytologic correlation and relative abundance.

## Decision Framework: Topical, Systemic, or Both

The treatment algorithm begins with classification. Surface pyoderma, including intertrigo and acute moist dermatitis, responds to topical therapy alone in nearly all cases. Superficial pyoderma, encompassing impetigo, superficial bacterial folliculitis, and mucocutaneous pyoderma, is also treated topically as first-line therapy according to the [ISCAID synopsis of antimicrobial use guidelines](https://pubmed.ncbi.nlm.nih.gov/40556037/). Systemic antimicrobials are reserved for deep pyoderma and for superficial disease that has not responded to topical treatment.

The following table summarizes the decision points that move a case from topical-only management toward systemic therapy.

| Clinical Scenario | First-Line Approach | Trigger to Escalate | Systemic Therapy Indicated |
|---|---|---|---|
| Surface pyoderma (intertrigo, hot spot) | Topical chlorhexidine or benzoyl peroxide | Lesion expansion despite 5 to 7 days of topical therapy | Rarely, investigate underlying cause |
| Superficial pyoderma, first episode | Topical therapy alone | No improvement after 14 days of consistent topical treatment | Only after culture confirms resistance or owner compliance failure |
| Superficial pyoderma, recurrent | Topical therapy plus investigation of primary cause | Third episode in 12 months | Culture-guided systemic therapy with concurrent topical treatment |
| Deep pyoderma at presentation | Topical adjunctive therapy plus systemic antimicrobials | Clinical deterioration within 48 to 72 hours | Immediate, culture-guided where possible |
| Rods on cytology | Culture before any antimicrobial | Not applicable | Culture-guided systemic therapy |

Owner compliance is a frequent and underappreciated reason for topical treatment failure. The clinician should confirm that the owner can apply the product to all affected areas, that the dog tolerates application, and that the frequency of application matches the label recommendation. When compliance is doubtful, systemic therapy may be chosen for practical reasons, but this decision should be documented and revisited.

## Systemic Antimicrobial Selection and Monitoring

When systemic therapy is indicated, the choice of agent should follow culture and susceptibility results whenever possible. For cases where empiric therapy is unavoidable because of the severity of disease or delay in culture results, the [ISCAID guidelines](https://pubmed.ncbi.nlm.nih.gov/40338805/) recommend agents with a narrow spectrum and established efficacy against staphylococci. The initial systemic course is two weeks for superficial pyoderma and three weeks for deep pyoderma, followed by re-examination to assess progress. Extension of therapy beyond these intervals requires documented evidence of ongoing infection.

The table below compares systemic options with their resistance considerations. Current formulary and label references must be consulted for dosing, as recommendations vary by region and formulation.

| Drug Class | Representative Agents | Resistance Considerations | Clinical Notes |
|---|---|---|---|
| Beta-lactams | Amoxicillin-clavulanic acid, cephalexin | MRSP isolates are resistant to all beta-lactams | First-line empiric choice when MRSP is not suspected |
| Lincosamides | Clindamycin | Inducible resistance may not be detected on routine testing | Avoid when MRSP is confirmed or suspected |
| Potentiated sulfonamides | Trimethoprim-sulfamethoxazole | Variable resistance in MRSP populations | Useful alternative for susceptible isolates |
| Fluoroquinolones | Enrofloxacin, marbofloxacin | Rapid resistance development, reserve for confirmed susceptibility | Avoid as empiric monotherapy |
| Chloramphenicol | Chloramphenicol | Resistance uncommon but possible | Consider for multidrug-resistant MRSP when susceptibility is confirmed |
| Aminoglycosides | Gentamicin, amikacin | Nephrotoxicity and ototoxicity risk | Systemic use limited, topical or regional use preferred |

Monitoring during systemic therapy includes re-examination at the end of the initial treatment period, cytologic assessment of resolving lesions, and evaluation for adverse drug effects. Clinical improvement should be evident by the first recheck. Lack of improvement at two weeks for superficial or three weeks for deep pyoderma demands reassessment of the diagnosis, culture confirmation, and investigation of the primary underlying disease. The [review on topical therapy for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/36921021/) notes that systemic antibiotics should be limited to severe cases to reduce selection pressure for multidrug-resistant bacteria, and this principle should guide every prescribing decision.

## Documentation and Stewardship Records

Every antimicrobial prescription for pyoderma should be documented with the indication, the classification of pyoderma, the cytologic findings, the drug selected, the dose, the planned duration, and the recheck date. When culture is performed, the organizm, susceptibility profile, and the clinical rationale for the chosen drug should be recorded. This documentation supports the [AVMA antimicrobial stewardship principles](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) and provides a basis for reviewing prescribing patterns within the practice.

Practices should track the proportion of pyoderma cases managed with topical therapy alone, the rate of culture submission for recurrent cases, and the prevalence of MRSP isolates. These metrics identify opportunities for improvement and document the practice's contribution to resistance mitigation. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) frame antimicrobial stewardship as a component of veterinary professional responsibility, and practice-level surveillance supports this obligation.

## Recognized Complications and Failure Modes

The most common reason a pyoderma fails to resolve is not antimicrobial resistance but an untreated or unrecognised primary disease. Recurrent or non-responsive pyoderma should trigger a search for atopic dermatitis, endocrinopathy, parasitic infestation, or keratinisation defects before antimicrobial therapy is escalated. The 2025 ISCAID guidelines emphasize that cytology should be performed in all cases before antimicrobials are used, and that topical therapy alone is the treatment of choice for surface and superficial pyodermas [ISCAID antimicrobial use guidelines for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/40338805/). When systemic therapy is required, it should be reserved for deep pyoderma and for superficial pyoderma that has failed topical treatment [ISCAID synopsis of antimicrobial use guidelines for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/40556037/).

Early detection of treatment failure depends on scheduled re-examination. The ISCAID guidelines recommend an initial systemic treatment period of 2 weeks for superficial and 3 weeks for deep pyoderma, followed by reassessment to determine whether continuation, change, or discontinuation is appropriate [ISCAID antimicrobial use guidelines for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/40338805/). A dog that shows no cytological or clinical improvement within this window should be re-cultured, and the primary disease investigation should be intensified.

Methicillin-resistant Staphylococcus pseudintermedius (MRSP) is a recognized complication in recurrent and previously treated cases. A systematic review and meta-analysis of Asian studies published between 2015 and 2024 found a pooled MRSP prevalence of 30.7% among pyoderma isolates, with broader resistance to oxacillin, clindamycin, and other agents compared with methicillin-susceptible strains [prevalence and antibiotic resistance profile of Staphylococcus pseudintermedius in pyodermic dogs in Asia](https://pubmed.ncbi.nlm.nih.gov/42065810/). These figures vary by region and practice setting, but they justify culture-guided selection whenever a case has failed an appropriate first-line course.

## Common Errors and Corrective Actions

Less experienced clinicians often prescribe systemic antibiotics for superficial pyoderma that would respond to topical therapy alone. The 2018 narrative review by Loeffler and Lloyd notes that canine pyoderma frequently leads to systemic antimicrobial prescription, and that the emergence of multidrug-resistant staphylococci now limits the effectiveness of traditional treatment recommendations [what has changed in canine pyoderma: a narrative review](https://pubmed.ncbi.nlm.nih.gov/29704943/). The corrective action is to classify the depth of infection before prescribing and to exhaust topical options first.

A second common error is discontinuing systemic therapy as soon as the skin looks improved, instead of treating beyond clinical resolution. This promotes recurrence and selects for resistant subpopulations. The corrective action is to define the expected treatment duration at the outset and to re-examine instead of refill by telephone.

A third error is interpreting a culture result without correlating it with cytology. A swab that grows a commensal or contaminant can misdirect therapy. The discriminating check is to compare the cultured organizm with the morphology seen on cytology and to confirm that the organizm is present in significant numbers within neutrophils.

## Limitations of the Evidence and Areas of Expert Difference

The evidence base for canine pyoderma management has important gaps. The 2025 ISCAID guidelines were developed from a systematic review of English-language treatment studies up to December 2023, with quality assessed using SORT criteria and combined with author consensus [ISCAID antimicrobial use guidelines for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/40338805/). This means that several recommendations rest on expert opinion instead of high-quality trials, particularly for treatment duration and for the choice of systemic agent in multidrug-resistant cases.

Expert opinion still differs on the role of newer topical and physical modalities. Fluorescent light energy has shown promise in an exploratory study of multidrug-resistant deep pyoderma and interdigital furunculosis, where it produced clinical resolution without adjunctive antibiotics in a small cohort [fluorescent light energy in the management of multidrug resistant canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/36297254/). This is a single exploratory study, and it should not be read as a general rule. The same review that summarizes classic topical agents such as chlorhexidine, benzoyl peroxide, and ethyl lactate also notes that new alternatives have been explored over the past decade, but that clinical efficacy data remain limited for many of them [topical therapy for canine pyoderma: what is new](https://pubmed.ncbi.nlm.nih.gov/36921021/).

## Referral, Consultation, and Reporting

Referral to a veterinary dermatologist is warranted when a case has failed two appropriately selected and completed courses of therapy, when the primary disease cannot be identified, when multidrug-resistant infection requires systemic treatment options outside routine formularies, or when adverse drug reactions complicate therapy. Laboratory involvement is indicated for culture and susceptibility testing in any recurrent case and for histopathology when neoplasia, autoimmune disease, or deep fungal infection enters the differential.

Regulatory reporting obligations vary by jurisdiction. Veterinarians should be aware of their local requirements regarding extralabel drug use and reporting of resistant infections. The FDA Center for Veterinary Medicine provides regulatory information on approved animal drugs, labeling, and extralabel use policy [FDA Center for Veterinary Medicine animal drug information](https://www.fda.gov/animal-veterinary), while the AVMA publishes professional guidance on judicious antimicrobial use and stewardship principles [AVMA antimicrobial use and stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). International standards for surveillance and disease control are set out in the WOAH Terrestrial Animal Health Code [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). Clinicians should confirm the specific requirements that apply in their own region.

| Observation | Likely Cause | Discriminating Check |
|---|---|---|
| No improvement after 2 weeks of systemic therapy | Wrong drug, wrong dose, or resistant organizm | Repeat cytology and culture with susceptibility testing |
| Recurrence within weeks of stopping therapy | Untreated primary disease | Full dermatological workup for atopy, endocrinopathy, parasites |
| Culture grows organizm not seen on cytology | Contaminant or sampling error | Repeat cytology, correlate morphology with culture result |
| Skin worse during therapy | Adverse drug reaction or secondary yeast overgrowth | Cytology for Malassezia, review drug history |
| MRSP isolated on culture | Prior antimicrobial pressure | Treat based on susceptibility, review infection control and owner hygiene |

## Frequently Asked Questions

### How Do I Manage Pyoderma When the Owner Cannot Afford Culture or Repeated Visits?

Cost constraints are common. Start with cytology to confirm bacterial infection and exclude other differentials. If cytology shows cocci, begin topical therapy with chlorhexidine or benzoyl peroxide, which remain effective first-line options with a low resistance profile [topical therapy for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/36921021/). Reserve systemic antibiotics for deep pyoderma or superficial disease that fails topical therapy, per current ISCAID guidance [ISCAID antimicrobial use guidelines](https://pubmed.ncbi.nlm.nih.gov/40338805/). Schedule one recheck at the end of the initial treatment period instead of multiple visits. If the owner cannot afford a recheck, request photographs and a phone consultation. Document the financial limitation and the plan agreed upon. Culture remains preferable for recurrent or suspected resistant cases, but a single cytology-guided topical trial is a reasonable first step when resources are limited.

### What Should I Do When Culture and Susceptibility Testing Is Not Readily Available?

When laboratory access is delayed or unavailable, rely on cytology and clinical response. Collect a culture swab before starting systemic therapy if resistance is suspected, then store it appropriately until submission is possible. In the interim, select a systemic agent based on local resistance patterns and the patient's prior antimicrobial history. The pooled prevalence of methicillin-resistant Staphylococcus pseudintermedius in Asian studies is approximately 30%, with broader resistance to oxacillin, clindamycin, and other agents [prevalence and resistance profile of S. pseudintermedius](https://pubmed.ncbi.nlm.nih.gov/42065810/). If the patient has received multiple antibiotic courses previously, choose an agent from a different class. Re-examine at the recommended intervals and extend treatment only if clinical progress is documented. If no improvement occurs within the expected timeframe, pursue culture through a referral laboratory or consult a veterinary dermatologist.

### How Do I Explain Antimicrobial Stewardship to a Client Who Expects Antibiotics?

Frame the discussion around the dog's infection, not abstract policy. Explain that most surface and superficial pyodermas resolve with medicated baths and wipes alone, and that systemic antibiotics carry risks including resistance and adverse effects [synopsis of ISCAID pyoderma guidelines](https://pubmed.ncbi.nlm.nih.gov/40556037/). Use the phrase "targeted treatment" instead of "withholding antibiotics." Show the client the cytology findings and explain that topical therapy reaches the infection directly at high concentration. For cases requiring systemic drugs, explain that culture identifies the specific bacterium and the antibiotic most likely to work, avoiding ineffective drugs. Emphasize that finishing the full course and returning for rechecks prevents recurrence and reduces the need for stronger antibiotics later. Written aftercare instructions with bathing frequency and technique improve compliance.

### What Records Should I Keep for Antimicrobial Prescribing in Pyoderma Cases?

Record the pyoderma classification, cytology results, and the rationale for topical versus systemic therapy. For systemic prescriptions, document the drug, dose, duration, and the clinical justification, including why topical therapy alone was insufficient. Note any previous antibiotic courses and their outcomes. If culture was performed, record the organizm, susceptibility results, and how the result guided drug selection. The AVMA provides practice resources on judicious antimicrobial use and stewardship principles that can inform record templates [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). Include a recheck plan and the criteria for extending or stopping therapy. These records support clinical continuity, identify patterns of resistance in your practice, and provide defensible documentation if prescribing is reviewed.

### Does This Approach Apply to Other Species or to Methicillin-Resistant Infections?

The principles apply broadly, but species-specific differences exist. The ISCAID guidelines address canine pyoderma specifically [ISCAID antimicrobial use guidelines](https://pubmed.ncbi.nlm.nih.gov/40338805/). Feline skin infections are less common and often have different underlying causes. In dogs, methicillin-resistant staphylococci require the same diagnostic logic, with culture and susceptibility testing before systemic therapy. Topical therapy remains valuable for resistant infections because chlorhexidine and similar agents retain activity regardless of methicillin resistance status [topical therapy for canine pyoderma](https://pubmed.ncbi.nlm.nih.gov/36921021/). For deep pyoderma caused by resistant organizms, systemic therapy should be based on culture results and continued until clinical resolution, which may exceed the standard three-week recheck. Consult current formularies for drug selection and monitor for adverse effects throughout treatment.

### How Do I Handle Recurrent Pyoderma Despite Apparent Compliance?

Recurrent disease almost always indicates an unresolved primary cause. Re-evaluate for allergic skin disease, endocrinopathy, or anatomical factors such as deep skin folds. Perform cytology at each recurrence to confirm active infection and reassess the bacterial population. If the patient has received multiple systemic courses, culture and susceptibility testing are indicated before further systemic therapy. Consider whether the previous topical protocol was practical for the owner, bathing frequency and contact time are common points of failure. The emergence of multidrug-resistant staphylococci has changed how recurrent pyoderma must be managed, with greater emphasis on identifying and controlling the underlying disease [changes in canine pyoderma management](https://pubmed.ncbi.nlm.nih.gov/29704943/). Refer to a dermatologist if the primary cause cannot be identified or controlled, or if resistant infection persists despite appropriate therapy.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Topical therapy for canine pyoderma: what is new?](https://pubmed.ncbi.nlm.nih.gov/36921021/). 2023.
- [Prevalence and antibiotic resistance profile of Staphylococcus pseudintermedius in pyodermic dogs in Asia: a systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/42065810/). 2026.
- [What has changed in canine pyoderma? A narrative review.](https://pubmed.ncbi.nlm.nih.gov/29704943/). 2018.
- [Fluorescent Light Energy in the Management of Multi Drug Resistant Canine Pyoderma: A Prospective Exploratory Study.](https://pubmed.ncbi.nlm.nih.gov/36297254/). 2022.
- [Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID).](https://pubmed.ncbi.nlm.nih.gov/40338805/). 2025.
- [Synopsis of the antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID).](https://pubmed.ncbi.nlm.nih.gov/40556037/). 2025.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- Antimicrobial Stewardship in Canine Sepsis: Empiric Therapy and De-escalation
- [Antimicrobial Stewardship in Canine Otitis: Culture, Susceptibility, and Topical Therapy](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-otitis)
- [Antimicrobial Stewardship in Canine Bite Wounds: Culture and Susceptibility-Driven Therapy](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-bite-wounds)
- Antimicrobial Stewardship in Canine Skin Infections: Topical Therapy as First-Line
- Antimicrobial Stewardship in Canine Wound Management: Topical vs Systemic Therapy

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.